Literature DB >> 10393720

Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes.

J Cloos1, E J Nieuwenhuis, D I Boomsma, D J Kuik, M L van der Sterre, F Arwert, G B Snow, B J Braakhuis.   

Abstract

BACKGROUND: Susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes may reflect the way a person deals with carcinogenic challenges. This susceptibility (also referred to as mutagen sensitivity) has been found to be increased in patients with environmentally related cancers, including cancers of the head and neck, lung, and colon, and, in combination with carcinogenic exposure, this susceptibility can greatly influence cancer risk. The purpose of this study was to assess the heritability of mutagen sensitivity.
METHODS: Heritability was determined by use of a maximum likelihood method that employed the FISHER package of pedigree analysis. Bleomycin-induced breaks per cell values for 135 healthy volunteers without cancer were determined. These individuals were from 53 different pedigrees and included 25 monozygotic twin pairs (n = 50), 14 pairs of dizygotes (twin pairs and siblings, n = 28), and 14 families selected on the basis of a first-degree relative who was successfully treated for head and neck cancer and who had no sign of recurrence for at least 1 year. All data were analyzed simultaneously, and different models of familial resemblance were fitted to the data. All P values are two-sided.
RESULTS: Our results showed no evidence for the influence of a shared family environment on bleomycin-induced chromatid breaks. Genetic influences, however, were statistically significant (P =. 036) and accounted for 75% of the total variance.
CONCLUSIONS: The high heritability estimate of the susceptibility to bleomycin-induced chromatid breaks indicates a clear genetic basis. The findings of this study support the notion that a common genetic susceptibility to DNA damage--and thereby a susceptibility to cancer--may exist in the general population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10393720     DOI: 10.1093/jnci/91.13.1125

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  23 in total

1.  Functional characterization of Ape1 variants identified in the human population.

Authors:  M Z Hadi; M A Coleman; K Fidelis; H W Mohrenweiser; D M Wilson
Journal:  Nucleic Acids Res       Date:  2000-10-15       Impact factor: 16.971

2.  An in vitro approach to study chromosomal DNA damage.

Authors:  M Bala; L Mathew
Journal:  Mol Biol Rep       Date:  2001       Impact factor: 2.316

3.  Influence of polymorphisms at loci encoding DNA repair proteins on cancer susceptibility and G2 chromosomal radiosensitivity.

Authors:  Craig S Wilding; Gillian B Curwen; E Janet Tawn; Xiaohua Sheng; Jeanette F Winther; Ranajit Chakraborty; John D Boice
Journal:  Environ Mol Mutagen       Date:  2007-01       Impact factor: 3.216

4.  Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.

Authors:  Wei Zhang; R Stephanie Huang; M Eileen Dolan
Journal:  Trends Cancer Res       Date:  2008

Review 5.  Pharmacogenomic discovery using cell-based models.

Authors:  Marleen Welsh; Lara Mangravite; Marisa Wong Medina; Kelan Tantisira; Wei Zhang; R Stephanie Huang; Howard McLeod; M Eileen Dolan
Journal:  Pharmacol Rev       Date:  2009-12       Impact factor: 25.468

Review 6.  Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity.

Authors:  Christine M Hartford; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2007-09       Impact factor: 2.533

7.  DNA repair and mutagen sensitivity of epithelial cells and lymphocytes in oropharyngeal cancer.

Authors:  Maximilian Reiter; Philipp Baumeister; Sonja Jaiser; Andreas Reiss; Sabina Schwenk-Zieger; Norbert Kleinsasser; Ulrich Harréus
Journal:  Oncol Lett       Date:  2011-09-09       Impact factor: 2.967

8.  Mutagen sensitivity, tobacco smoking and breast cancer risk: a case-control study.

Authors:  Ourania Kosti; Celia Byrne; Katherine L Meeker; Kenshata M Watkins; Christopher A Loffredo; Peter G Shields; Marc D Schwartz; Shawna C Willey; Costanza Cocilovo; Yun-Ling Zheng
Journal:  Carcinogenesis       Date:  2010-01-28       Impact factor: 4.944

Review 9.  Pharmacogenetics and pharmacogenomics of anticancer agents.

Authors:  R Stephanie Huang; Mark J Ratain
Journal:  CA Cancer J Clin       Date:  2009 Jan-Feb       Impact factor: 508.702

Review 10.  Use of cell lines in the investigation of pharmacogenetic loci.

Authors:  Wei Zhang; M Eileen Dolan
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.